RAP 0.00% 20.5¢ raptor resources limited

Ann: ResApp Announces SleepCheck, a Sleep Apnoea Screening App, page-40

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 441 Posts.
    lightbulb Created with Sketch. 322
    Target market. 1 billion people.

    SAN DIEGO--(BUSINESS WIRE)-- A new data analysis presented by ResMed (NYSE: RMD, ASX: RMD) this week at the ATS 2018 International Conferenceindicates that the prevalence of sleep apnea impacts more than 936 million people worldwide – nearly 10 times greater than previous estimates.This press release features multimedia. View the full release here: The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. The study “Global Prevalence of Obstructive Sleep Apnea (OSA)” was conducted by an international panel of leading researchers seeking to provide a clear scope of the impact of the chronic sleep-disordered breathing condition. The previous estimation of OSA prevalence (100 million) came from a 2007 World Health Organization study that used methods and data available at the time. By analyzing technology improvements in detecting OSA and underreported statistics from other areas of the world, this latest study depicts an impacted population significantly larger than previously identified.
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.